Polo-like kinase 4 inhibition: a strategy for cancer therapy?

Andrew J Holland; Don W Cleveland

doi:10.1016/j.ccr.2014.07.017

Polo-like kinase 4 inhibition: a strategy for cancer therapy?

Cancer Cell. 2014 Aug 11;26(2):151-3. doi: 10.1016/j.ccr.2014.07.017.

Authors

Andrew J Holland¹, Don W Cleveland²

Affiliations

¹ Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: aholland@jhmi.edu.
² Ludwig Institute for Cancer Research and Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: dcleveland@ucsd.edu.

Abstract

In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

Publication types

Comment

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Breast Neoplasms / enzymology*
Female
Humans
Indazoles / pharmacology*
Indoles / pharmacology*
Protein Serine-Threonine Kinases / metabolism*

Substances

2-(3-(4-((2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one
Antineoplastic Agents
Indazoles
Indoles
PLK4 protein, human
Protein Serine-Threonine Kinases

Grants and funding

R01 GM029513/GM/NIGMS NIH HHS/United States